Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

by Tianfang Shao, Mariana R. Neves, Molly Franke, Carole Mitnick, Jennifer Furin, Ted Cohen, Reza Yaesoubi Background Fluoroquinolones (FQs) are a cornerstone of most all-oral, shorter regimens endorsed by the World Health Organization for the treatment of rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB).

Knowledge of resistance to FQs can help guide regimen selection at the point of care. In settings where rapid testing for FQ resistance is unavailable, prediction models could support treatment decisions by identifying FQ resistance based on patient characteristics observable…

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: PLOS Medicine · September 15, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.